Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase 30,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

Read more at globenewswire.com